



ATTORNEY DOCKET: 59866.000002

JFL
PATENT
1642
S

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 09/546,573 Confirmation No.: 3408
Applicant : Mads HOLLEN-ANDERSEN et al.
Filed : April 10, 2000
Title : TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES
TYPE-1 (TIMP-1) AS A CANCER MARKER
TC/Art Unit : 1642
Examiner: Stephen L. Rawlings, Ph. D.

Docket No. : 59866.000002
Customer No. : 21967

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08A (modified) for consideration and request the reference cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Applicants respectfully point out that the submission of the listed reference in this Supplemental Information Disclosure Statement is not an admission that it is prior art or that it is material to patentability of any claims of the application. Also, the submission of this 2nd Supplemental Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited reference, a copy of the cited reference is enclosed with this communication. In considering the cited reference, it may be noted by the Examiner that certain of the reference may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be

11/10/2004 SZEWDIE1 0000009 500206 09546573

01 FC:1806 180.00 DA

construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited reference. Any such markings were either present on the copy of the cited reference obtained by the associated individuals, or were made thereon during the study of the reference by the associated individuals. Applicants respectfully point out that the submission of the listed reference in this Supplemental Information Disclosure Statement is not an admission that it is prior art or that it is material to patentability of any claims of the application. Also, the submission of this Supplemental Information Disclosure Statement is not an indication that a search has been made by Applicants.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.


In accordance with 37 C.F.R. § 1.97(c), this Supplemental Information Disclosure Statement is being filed (i) before the mailing date of a final Office Action for the above-identified patent application; (ii) before the mailing date of a Notice of Allowance for the above-identified patent application; or (iii) before the mailing date of an Office Action that otherwise closes prosecution in the above-identified patent application. Accordingly, this Supplemental Information Disclosure Statement is accompanied by an authorization to charge the undersigned's Deposit Account No. 50-0206 in the amount of \$180.00.

In the event any variance exists between the amount enclosed and the Patent Office charges, please charge or credit any difference to the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

By:



Stanislaus Aksman
Registration No. 28,562

Dated: November 8, 2004

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)
SA/sdw

